Roche Venture Fund — Full Portfolio
40 tracked investments · listed companies and verified rows first
Enliven Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small molecule therapeutics using a precision medicine approach, with a focus on oncology and hematology.
BiotechHealthtechBoulder, US
Sam Kintz(Co-founder and Head of Pipeline)inJoe Lyssikatos(Co-founder and Research Fellow)Anish Patel(Co-founder and Chief Operating Officer)Rick Fair(Chief Executive Officer and Member of the Board of Directors)inHelen Collins(Chief Medical Officer)inBen Hohl(Chief Financial Officer and Head of Corporate Development)in
Co-investors5AM VenturesOrbiMedPfizer Venture InvestmentsARCH Venture PartnersBay City CapitalNew Enterprise Associates (NEA)+1 more
Entrada Therapeutics is a biotech company developing intracellular therapeutics based on its proprietary EEV Platform, aimed at reaching previously inaccessible or undruggable disease-causing targets inside cells.
BiotechHealthtechBoston, US
Natarajan Sethuraman(Executive Officer)inNerissa Kreher(Executive Officer)inKory Wentworth(Executive Officer)inDipal Doshi(Chief Executive Officer)inNathan Dowden(Executive Officer)inNatarajan Sethuraman, PhD(President of Research and Development)
Co-investors5AM VenturesAgent CapitalMPM BioImpactMRL Ventures FundTCG Crossover
Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon
Riley Ennis(Co-Founder and Chief Product Officer)inCharles Roberts(Director)inGabriel Otte(Director)inAdam Stone(Chief Executive Officer and Director)Michael Altman(Chief Business Officer and Director)Shmuel (Sam) M. Cohn(Chief Financial Officer)
Co-investorsRA CapitalAgent CapitalAME Cloud VenturesAndreessen HorowitzArtis VenturesAsset Management Company+9 more
BiotechSouth San Francisco, US
Grant E. Pickering(Chief Executive Officer)Ashish Khanna(Executive Officer)Jeff Fairman(Executive Officer)
BoardTracy Saxton(Director)William Newell(Director)Kurt von Emster(Director)in
Co-investorsAbingworthCTI Life Sciences Fund L.P.Foresite CapitalFrazier Life SciencesJanus Henderson InvestorsLongitude Capital+4 more
COUR develops antigen-specific immunotherapies that reprogram the immune system to treat the underlying causes of autoimmune and immune-mediated diseases while preserving normal immune function.
BiotechHealthtech
Co-investorsAlpha Wave GlobalLumira VenturesAngelini VenturesJDRF T1D Fund
DiogenX is a preclinical-stage biotech company developing biologic therapeutics aimed at restoring insulin-producing beta cells for people with Type 1 diabetes.
BiotechDeep TechDigital HealthHealthtechMarseille, FR
Benjamin Charles(Co-Founder & CEO)inPatrick Collombat(Co-Founder & Scientific Advisor)inJean-Pascal Tranié(Co-Founder)in
Co-investorsAdBio partnersBoehringer Ingelheim Venture FundSunstone CapitalJDRF T1D Fund
Komed Health provides a secure, real-time communication platform designed for hospitals to enhance collaboration among care teams and improve patient care delivery.
Digital HealthEnterprise SoftwareHealthtechSaaSZurich, CH
Marc(Technical Co-founder)
Co-investorsSICTIC
Soteria Biotherapeutics develops protein-based biotherapeutics and small molecules using its LITE Switch technology platform for drug discovery and development across oncology, immune-oncology, and inflammatory disease indications.
BiotechDeep TechHealthtechMedical DevicesWellness & FitnessSan Francisco, US
Zachary B. Hill(SVP, Chief Scientific Officer and Co-founder)Jim Wells(Co-founder, Scientific Advisory Board Chair)Kristine M Ball(Executive Officer, Director)inZachary Hill(Executive Officer, Director)in
BoardNisha Marathe(Director)David Allison(Director)in
Co-investors5AM VenturesNovartis Venture FundVersant VenturesBioGeneration VenturesWestlake Village BioPartners
SpliceBio develops genetic medicines using a proprietary protein splicing platform to treat diseases caused by mutations in large genes.
BiotechDeep TechDigital HealthBarcelona, ES
Dr. Vila-Perelló(CEO)Dr. Frutos(Co-founder)
Co-investorsNovartis Venture FundSanofi VenturesYsios CapitalAsabys PartnersCriteria Bio VenturesNew Enterprise Associates (NEA)+3 more
Vivet Therapeutics is a clinical-stage biotechnology company developing recombinant adeno-associated virus (rAAV) gene therapies for rare, inherited metabolic diseases, including Wilson's Disease and cerebrotendinous xanthomatosis.
BiotechHealthtechParis, FR
Co-investorsHealthCapKurma PartnersNovartis Venture FundYsios CapitalColumbus Venture PartnersEurazeo+1 more
BiotechWatertown, US
Edward Mascioli(Executive Officer)Andrew Myers(Director)
BoardMarkus Goebel(Director)Henry Skinner(Director)inVikas Goyal(Director)Raj Parekh(Director)in
Board seatAnja Harmeier· per SEC Form D · $20M raise · filed Mar 2018
Co-investorsAdvent Life SciencesGurnet Point CapitalNovartis Venture Fund
Aligos is a clinical-stage biotechnology company developing therapeutics for liver and viral diseases, including chronic hepatitis B virus (HBV) infection and MASLD/MASH.
BiotechHealthtechSouth San Francisco, US
Leonid Beigelman(President)inLawrence M. Blatt(Chairman, President & CEO (Co-founder))inHardean Achneck(Executive Officer)inBrian Dowd(Executive Vice President - Controller)inLucinda Quan(Executive Vice President - General Counsel)inJulian Symons(Executive Vice President, Chief Scientific Officer)in
Co-investorsMPM BioVentures 2014Vivo Capital
Portfolio company that completed a successful 2018 biotech IPO, resulting in a 9x return for RiverVest.
BiotechSan Carlos, US
Nenad Tomasevic(Executive Officer)Christopher Bebbington(Executive Officer, Director)Alejandro Dorenbaum(Executive Officer)
BoardFarah Champsi(Director)inJohn McKearn(Director)inPeter Moldt(Director)
Co-investorsAlta PartnersNew Enterprise Associates (NEA)RiverVest Venture PartnersSamsara BioCapital
Co-investorsAvego BioScience CapitalBioGenerator VenturesPerot JainRiverVest Venture PartnersSR One Capital Management
Bonum Therapeutics develops antibody-controlled protein therapeutics that remain inactive until bound to their target, using a sensor-domain mechanism to deliver regulated, targeted activity.
BiotechHealthtechSeattle, US
John Mulligan(Executive Officer, Director, Promoter)inNeela Patel(Executive Officer)inDiane Hollenbaugh(Executive Officer)in
BoardSamuel Bjork(Director)inMonique Schiersing(Director)inJohn McKearn(Director)in
Co-investorsRiverVest Venture PartnersVivo Capital3x5 PartnersCodon CapitalDigitalis Ventures
Enthera Srl is a privately held pharmaceutical company founded in 2016 and based in Milan, Italy.
BiotechHealthtechMilan, IT
Co-investorsSofinnova PartnersIndaco Venture PartnersAbbVieJDRF T1D Fund
Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.
BiotechMedical DevicesSan Mateo, US
Ann Lee-Karlon(Executive Officer, Director)inMitchell Mutz(Executive Officer, Director)James Wells(Director)
BoardSamuel Bjork(Director)inAlexandra Cantley(Director)inSeiji Miyahara(Director)in
Co-investorsAvego BioScience CapitalGV (Google Ventures)Mission BiocapitalNovartis Venture FundSamsara BioCapitalTaiho Ventures, LLC+4 more
Forcefield Therapeutics develops cardioprotective proteins for the treatment of cardiac disease, with an initial focus on myocardial infarction (heart attack).
BiotechHealthtechMedical Devices
John
GlycoEra develops glycan-based therapeutics, applying glycoengineering technology to create biologic drugs.
BiotechHealthtechNewton, US
Ganesh V. Kaundinya(President & CEO)in
Co-investors5AM VenturesCatalio Capital Management, LPLifeArc VenturesSixty Degree CapitalSofinnova PartnersAgent Capital+1 more
Portfolio company acquired by Roche.
BiotechSeattle, US
John Mulligan(Executive Officer, Director, Promoter)inMitchell Mutz(Director)Nicholas Walrod(Director)
BoardJohn McKearn(Director)inKarl Handelsman(Director)
Co-investorsDigitalis VenturesRiverVest Venture Partners
The National Kidney Foundation works to eliminate preventable kidney disease, accelerate innovation in patient care, and address structural inequities in kidney treatment and transplantation services.
HealthtechImpact & Social Good
Co-investorsYsios CapitalBioGeneration VenturesEpidarex CapitalScottish National Investment BankSofinnova Partners
Kumquat Biosciences is a biotech company developing small-molecule cancer therapeutics, combining drug discovery and clinical expertise to advance new oncology treatments.
BiotechSan Diego, US
Yi Liu(Executive Officer, Director)inYi Liu, Ph.D.(CEO)Lynn Yang(Director)
BoardCarl Gordon(Director)in
Co-investorsEcoR1 CapitalOrbiMed
Lysosomal Therapeutics Inc.
BiotechCambridge, US
Dimitri Krainc(Director)Robert Carpenter(Executive Officer, Director)Cornelis Been(Executive Officer, Director)
BoardSteven Hall(Director)Carole Nuechterlein(Director)inBernard Davitian(Director)
Co-investorsAtlas VentureHatteras Venture PartnersLilly VenturesOmega Funds
Minoryx is a registration-stage biotech company developing novel therapies for severe, orphan genetic diseases of the central nervous system, with a lead compound (leriglitazone) in clinical trials for conditions including cerebral adrenoleukodystrophy, Friedreich's Ataxia, and Rett syndrome.
BiotechDeep TechHealthtechMedical DevicesMataró, ES
Marc Martinell(Co-Founder & Chief Executive Officer)in
Co-investorsChiesi VenturesCriteria Bio VenturesFund+Invivo Capital PartnersKurma PartnersYsios Capital+2 more
Mironid is a drug development company building a pipeline of therapies targeting cAMP-degrading phosphodiesterase enzymes to treat Autosomal Dominant Polycystic Kidney Disease (ADPKD) and other rare kidney diseases.
BiotechMedical Devices
Adele Rowley(Chief Scientific Officer)in
Co-investorsEpidarex CapitalSofinnova PartnersBioGeneration VenturesScottish National Investment Bank
Mission Therapeutics develops therapeutics targeting deubiquitylating enzymes (DUBs), such as USP30, which regulate ubiquitylation and processes including mitophagy and protein homeostasis.
BiotechHealthtech
Co-investorsPfizer Venture InvestmentsSofinnova PartnersSR One Capital Management
NMD Pharma is a clinical-stage biotech company developing first-in-class small-molecule therapies that selectively target skeletal muscle to treat rare neuromuscular diseases and age-related conditions.
BiotechDeep TechHealthtechMedical DevicesAarhus, DK
Co-investorsJeito CapitalNovo HoldingsInkef
Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.
BiotechHealthtechMedical Devices
Ilise Lombardo(Chief Executive Officer)inVolker Knappertz(Executive Vice President of Research & Development)inMichael Samar(Chief Financial Officer)inRob Lasser(Chief Medical Officer)in
Co-investorsBioMedPartnersJeito CapitalSofinnova PartnersEQTEQT Life SciencesForbion+2 more
Sarepta develops precision genetic medicines for people with rare diseases, with a focus on rare neuromuscular conditions.
BiotechHealthtechCambridge, US
WILLIAM CIAMBRONE(Executive Officer)DOUGLAS S. INGRAM(Executive Officer, Director)inDAVID TYRONNE HOWTON(Executive Officer)SANDESH MAHATME(Executive Officer)GILMORE O'NEILL(Executive Officer)ALEXANDER CUMBO(Executive Officer)
Co-investorsAvoro Capital Advisors
Co-investorsLifeforce CapitalPfizer Venture InvestmentsDigitalis VenturesLightstone VenturesMorgenthalerSR One Capital Management
Soteria provides cybersecurity advisory services and solutions, including managed detection and response (MDR), virtual CISO support, domain monitoring, and Microsoft 365 risk management.
CybersecurityEnterprise SoftwareSaaSCharleston, US
Glenn Starkman(Co-Founder)inCHRISTOPHER O'ROURKE(Executive Officer)
Co-investorsCheckmate Capital Group LLC5AM Ventures
Tempest Therapeutics is a clinical-stage biotechnology company developing in vivo CAR-T cell therapies for autoimmune and oncology indications.
BiotechHealthtechBrisbane, US
Stephen Brady(Director)inMatthew Angel(Executive Officer, Director)Nicholas Maestas(Executive Officer)inThomas W. Dubensky, Jr.(Executive Officer, Director)Thomas Woiwode(Director)Geoffrey Nichol(Director)
Co-investorsF-Prime CapitalLAVLilly Asia VenturesNew Enterprise Associates (NEA)Quan CapitalVersant Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Alios BiopharmaAveXisMergeTheraPalladio BiosciencesPhoto of Civi BiopharmaPurigen Biosystems, Inc.Receptive BioVasculox
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.